Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: A randomized, placebo-controlled, parallel-group study

Clinical Therapeutics

Volumn 23, Issue 3, 2001, Pages 451-466

  Gupta, Samir ^a   Banfield, Christopher ^a   Kantesaria, Bhavna ^a   Marino, Mark ^a   Clement, Robert ^a   Affrime, Melton ^a   Batra, Vijay ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Azithromycin; Desloratadine; Electrocardiographic findings; Fexofenadine; Pharmacokinetics

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; AZITHROMYCIN; DESLORATADINE; FEXOFENADINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; FEMALE; HEADACHE; HUMAN; MALE; NORMAL HUMAN; PARALLEL DESIGN; QRS COMPLEX; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0035049380     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(01)80049-7     Document Type: Article

References (25)

1. Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist. 1st communication: Receptor selectivity, antihistaminic activity, and antiallergenic effects
2. 1-receptors
3. 1-receptor antagonist, in patients with seasonal allergic rhinitis. Assessment during the spring and fall allergy seasons
4. Desloratadine improved SAR symptoms in patients with mild-to-moderate asthma and SAR
5. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: A randomized, double-blind, placebo-controlled study
6. The metabolism of antihistamines and drug interactions: The role of cytochrome P450 enzymes
7. Metabolism of terfenadine associated with CYP3A(4) activity in human hepatic microsomes
8. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine
9. P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans
10. Terfenadine-ketoconazole interaction: Pharmacokinetic and electrocardiographic consequences
11. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin
12. Inter-relationship between substrates and inhibitors of human CYP3A and P-glycoprotein
13. The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions
14. Arrhythmogenic mechanisms of non-sedating antihistamines
15. Risk of torsades de pointes with non-cardiac drugs. Doctors need to be aware that many drugs can cause QT prolongation
16. An analysis of the time-relation of the electrocardiogram
17. Allegra® (fexofenadine) prescribing information
18. Lack of clinically relevant interaction between desloratadine and erythromycin
19. Effect of desloratadine on p-glycoprotein transport system (MDR1)
20. Grapefruit juice selectively inhibits OATP not P-glycoprotein
21. Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist. 2nd communication: Lack of central nervous system and cardiovascular effects
22. 1-receptor antagonist, has a cardiovascular safety profile similar to placebo
23. Lack of electrocardiographic effects of multiple high doses of desloratadine
24. Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole